Incannex announces final results from phase 1 clinical trial assessing safety and pharmacokinetics of ihl-675a

Melbourne, australia, may 02, 2023 (globe newswire) -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), (‘incannex' or the ‘company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received final results from the phase 1 clinical trial undertaken to assess pharmacokinetics and safety of the anti-inflammatory drug ihl-675a.
IXHL Ratings Summary
IXHL Quant Ranking